Candin for the Treatment of Common Warts

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

August 27, 2025

Study Completion Date

August 27, 2025

Conditions
Common Warts (Verruca Vulgaris)
Interventions
DRUG

Candin, Intradermal Solution

Injection at the base of the selected wart

DRUG

Placebo

Injection at the base of the selected wart

Trial Locations (18)

19073

Bryn Mawr Health Center, Newtown Square

23666

Velocity Clinical Hampton, Hampton

29303

Velocity Clinical Spartanburg, Spartanburg

35244

Cahaba Dermatology, Birmingham

48059

Hamzavi Dermatology, Fort Gratiot

60657

Kaminska Dermatology, Chicago

68144

Schlessinger MD, Omaha

71913

Dermatology Clinic of Arkansas, Hot Springs

72022

Arkansas Pediatric Clinic, Bryant

72916

Johnson Dermatology, Fort Smith

78660

Austin Institute for Clinical Research, Pflugerville

78759

DermResearch, Austin

80110

Velocity Clinical Englewood, Englewood

90805

Long Beach Research, Long Beach

91942

Velocity Clinical La Mesa, La Mesa

95815

Integrative Skin Research, Sacramento

02135

Integrated Dermatology of Newton-Brighton, Brighton

08009

Advocare Berlin Medical Associates, Berlin

Sponsors
All Listed Sponsors
lead

Nielsen BioSciences, Inc.

INDUSTRY

NCT05889845 - Candin for the Treatment of Common Warts | Biotech Hunter | Biotech Hunter